Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans.

Yi HA, Panepinto JC, Jacobs A.

Microb Pathog. 2012 Jan;52(1):25-30. doi: 10.1016/j.micpath.2011.09.007. Epub 2011 Oct 2.

PMID:
21983597
2.

Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae.

Pettoello-Mantovani M, Casadevall A, Smarnworawong P, Goldstein H.

AIDS Res Hum Retroviruses. 1994 Sep;10(9):1079-87.

PMID:
7826695
3.

Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.

Monari C, Retini C, Casadevall A, Netski D, Bistoni F, Kozel TR, Vecchiarelli A.

Eur J Immunol. 2003 Apr;33(4):1041-51.

4.
5.

Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

van de Wetering JK, Coenjaerts FE, Vaandrager AB, van Golde LM, Batenburg JJ.

Infect Immun. 2004 Jan;72(1):145-53.

6.

Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O, Alvarez M, Nakouzi A, Feldmesser M, Casadevall A.

Eukaryot Cell. 2007 Jan;6(1):48-59. Epub 2006 Nov 17.

7.

Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.

Villena SN, Pinheiro RO, Pinheiro CS, Nunes MP, Takiya CM, DosReis GA, Previato JO, Mendonça-Previato L, Freire-de-Lima CG.

Cell Microbiol. 2008 Jun;10(6):1274-85. doi: 10.1111/j.1462-5822.2008.01125.x. Epub 2008 Jan 30.

PMID:
18284419
8.

Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.

Zhang H, Zhong Z, Pirofski LA.

Infect Immun. 1997 Apr;65(4):1158-64.

10.

In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.

Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR.

J Infect Dis. 2001 Aug 15;184(4):479-87. Epub 2001 Jul 13.

PMID:
11471106
12.

Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.

Grijpstra J, Gerwig GJ, Wösten H, Kamerling JP, de Cock H.

Eukaryot Cell. 2009 Aug;8(8):1165-73. doi: 10.1128/EC.00013-09. Epub 2009 Jun 19.

13.

Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

De Jesus M, Nicola AM, Rodrigues ML, Janbon G, Casadevall A.

Eukaryot Cell. 2009 Jan;8(1):96-103. doi: 10.1128/EC.00331-08. Epub 2008 Oct 24.

14.

Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.

Pericolini E, Cenci E, Monari C, De Jesus M, Bistoni F, Casadevall A, Vecchiarelli A.

Cell Microbiol. 2006 Feb;8(2):267-75.

PMID:
16441437
15.

Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.

Pirofski LA.

Trends Microbiol. 2001 Sep;9(9):445-51. Review.

PMID:
11553457
16.

Receptor-mediated recognition of Cryptococcus neoformans.

Levitz SM.

Nihon Ishinkin Gakkai Zasshi. 2002;43(3):133-6. Review.

18.

Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.

Martinez LR, Moussai D, Casadevall A.

Infect Immun. 2004 Jun;72(6):3674-9.

19.

Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.

Feldmesser M, Casadevall A.

Front Biosci. 1998 Feb 1;3:d136-51. Review.

PMID:
9445465
20.

The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.

McFadden DC, De Jesus M, Casadevall A.

J Biol Chem. 2006 Jan 27;281(4):1868-75. Epub 2005 Nov 8.

Supplemental Content

Support Center